The 16th JFCR－ISCC
January 25-26, 2012
Miraikan (National Museum of Emerging Science and Innovation)
2-3-6, Aomi, Koto-ku, Tokyo, Japan
The 16th JFCR-ISCC: New Antitumor Agents under Development in the US, Europe and Japan
The 16th Symposium Program Committee
Hiroyuki Seimiya (Program Committee Chairman, Cancer Chemotherapy Ctr.)
Shiro Akinaga (Kyowa Hakko Kirin Co., Ltd.)
Naoya Fujita (Cancer Chemotherapy Ctr.)
Kiyohiko Hatake (Cancer Chemotherapy Ctr.)
Manabu Kawada (Inst. Microbial Chem.)
Atsushi Ohtsu (National Cancer Ctr. Hospital East)
Isamu Okamoto (Kinki Univ.)
Seiji Yano (Kanazawa Univ.)
January 25
11:00-13:00
Poster mounting
12:00-12:30
Committee Meeting
Opening remark
13:00-13:10
Mitsuaki Yoshida (Cancer Chemotherapy Center)
Opening remark
INew concepts for combination therapy and upcoming drugs
Chairpersons: Yves G. Pommier (National Cancer Institute)
Takao Yamori (Cancer Chemotherapy Center, JFCR)
13:10-13:45
Steven Grant (Virginia Commonwealth University)
New strategies for combining targeted therapies in hematologic malignancies
13:45-14:10
Takayuki Yoshino (National Cancer Center Hospital East)
TAS-102, a Novel Nucleoside Antitumor Agent for Metastatic Colorectal Cancer
14:10-14:20
Discussion
14:20-14:40
Coffee break
II New wave in antibody therapy
Chairpersons:Tomoki Naoe (Nagoya University)
Shiro Akinaga (Kyowa Hakko Kirin Co., Ltd.)
14:40-15:10
Wenru Song (Millennium)
Brentuximab Vedotin (Adcetris), an Antibody–Drug Conjugate for the Treatment of CD30-Positive Malignancies
15:10-15:40
Mark Sliwkowski (Genentech)
Multiple Approaches to Targeting HER/ErbB Receptors in Solid Tumors
15:40-15:50
Discussion
Poster Session
15:50-16:50
Junji Matsui (Eisai Co., Ltd)
Lenvatinib (E7080), a selective VEGFR/FGFR tyrosine kinase inhibitor (TKI) as a melanoma therapy for BRAF wild type melanoma and combination therapy with vemurafenib for V600E BRAF melanoma
Hiroyuki Arai (GlaxoSmithKline K.K.)
Epidemiology of breast cancer in Japan and pharmacological profile of lapatinib
Tadaaki Yamada (Kanazawa University)
Hepatocyte growth factor induces resistance to anti-epidermal growth factor receptor antibody in lung cancer
Hiroshi Tanaka (Chugai Pharmaceutical Co., Ltd.)
The selective class I PI3K inhibitor CH5132799 targets human cancers harboring oncogenic PIK3CA mutations
Makoto Kawatani (RIKEN)
Identification of novel tubulin polymerization inhibitors by proteomic profiling
Keiichiro Okuhira (National Institute of Health Sciences)
Degradation of estrogen receptor induced by a small hybrid molecule SNIPER(ER)
Satoshi Takagi (Cancer Chemotherapy Center)
Suppression of tumor metastasis by anti-Aggrus/podoplanin neutralizing antibodies
Osamu Kondoh (Chugai Pharmaceutical Co., Ltd.)
Targeting microtubule-associated protein 4 with novel small molecule CH4938056 confers antitumor activity under quasi in vivo conditions and in xenograft models
Haruyasu Murakami (Shizuoka Cancer Center)
The effect of CYP2C19 polymorphism on the tolerability of ARQ 197: Results from phase 1 trial in Japanese patients with metastatic solid tumors
Takahiro Ishiguro (Chugai Pharmaceutical Co., Ltd.)
Anti-Glypican3 antibody for treatment of human liver cancer
Takeharu Sakamoto (The Univesity of Tokyo)
Mint3 is a new molecular target for metastasis suppression
Ryoji Yao (Cancer Institute, JFCR)
Disruption of TACC3 leads to in vivo tumor regression by targeting spindle assembly.
16:50-18:30
Mixer
January 26
III Oncogene addiction targets (1)
Chairpersons: Mark Sliwkowski (Genentech)
Saburo Sone (JA Kochi Hospital)
9:00-9:35
Brian Schwartz (Arqule Inc)
Discovery and Development of Tivantinib, Non-ATP-Competitive Inhibitor Targeting MET Tyrosine Kinase for the Treatment of Solid Tumors.
9:35-10:00
Hiroshi Sakamoto (Chugai Pharmaceutical Co., Ltd.)
CH5424802: A selective ALK inhibitor
10:00-10:10
Discussion
10:10-10:30
Coffee break
Poster Discussion Session
Chairperson: Yoshikazu Sugimoto (Keio University)
10:30-11:45
Mentor: Dr. Bruce Chabner
Poster #: P1-P4
Mentor: Dr. Jaap Verweij
Poster #: P5-P8
Mentor: Dr. Yves G. Pommier
Poster #: P9-P12
12:00-12:30
Lunch
12:30-15:15
Poster removal
Special Lecture
Chairperson: Tetsuichiro Muto (JFCR)
12:45-13:35
Hideyuki Saya (Keio University)
Regulation and therapeutic targeting of cancer stem cells
Meet-the-Expert Seminars (1)
Chairperson: Ryuzo Ueda (Nagoya City University)
13:35-14:15
Bruce A. Chabner (MGH Cancer Center)
Epigenetics, the next frontier for cancer drug discovery
Meet-the-Expert Seminars (2)
Chairperson: Atsushi Ohtsu (National Cancer Center Hospital East)
14:15-14:55
Jaap Verweij (Erasmus University Medical Center)
Challenges and pitfalls in drug development. A personal experience
14:55-15:15
Coffee break
IV Oncogene addiction targets (2)
Chairpersons: Brian Schwartz (ArQule Inc.)
Yoshiro Niitsu (Sapporo Medical University)
15:15-15:45
Kathleen Schostack (Roche)
Development of vemurafenib: from target to personalized medicine and beyond
15:45-16:15
Erkut Bahceci (Astellas)
AC220 (quizartinib) for FLT3-ITD Positive Acute Myeloid Leukemia
16:15-16:25
Discussion
V Non-oncogene addiction targets
Chairpersons: Steven Grant (Virginia Commonwealth University)
Kiyohiko Hatake (Cancer Chemotherapy Center, JFCR)
16:25-17:00
Yves G. Pommier (National Cancer Institute)
Chk2: Targeting the DNA damage and cell cycle checkpoint
17:00-17:25
Toshihiko Doi (National Cancer Center Hospital East)
Targeting polo-like kinase 1 for cancer therapy
17:25-17:35
Discussion
Closing remark
17:35-17:45
Bruce A. Chabner (MGH)
Closing Remark
For further information
please contact:
Ritsuko Mihara
Cancer Chemotherapy Center, Japanese Foundation for Cancer Research
Ariake 3-8-31, Koto-ku, Tokyo 135-8550, Japan
TEL: 81-3-3570-0661 FAX: 81-3-3570-0484
Mail: ritsuko.mihara@jfcr.or.jp
